Literature DB >> 23287450

S100A1: A novel and essential molecular component for postischemic angiogenesis.

Betty Descamps, Paolo Madeddu, Costanza Emanueli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23287450      PMCID： PMC3616364          DOI： 10.1161/CIRCRESAHA.112.281022

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  16 in total

1.  The C terminus (amino acids 75-94) and the linker region (amino acids 42-54) of the Ca2+-binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibers.

Authors:  Patrick Most; Andrew Remppis; Cornelia Weber; Juliane Bernotat; Philipp Ehlermann; Sven T Pleger; Wolfgang Kirsch; Martin Weber; Dietmar Uttenweiler; Godfrey L Smith; Hugo A Katus; Rainer H A Fink
Journal:  J Biol Chem       Date:  2003-04-28       Impact factor: 5.157

2.  Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2).

Authors:  Patrick Most; Melanie Boerries; Carmen Eicher; Christopher Schweda; Philipp Ehlermann; Sven T Pleger; Eva Loeffler; Walter J Koch; Hugo A Katus; Cora-Ann Schoenenberger; Andrew Remppis
Journal:  J Biol Chem       Date:  2003-09-06       Impact factor: 5.157

Review 3.  Target selectivity in EF-hand calcium binding proteins.

Authors:  Shibani Bhattacharya; Christopher G Bunick; Walter J Chazin
Journal:  Biochim Biophys Acta       Date:  2004-12-06

4.  Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type-1 diabetic mice.

Authors:  C Emanueli; A Monopoli; N Kraenkel; M Meloni; S Gadau; I Campesi; E Ongini; P Madeddu
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

5.  Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model.

Authors:  Sven T Pleger; Changguang Shan; Jan Ksienzyk; Raffi Bekeredjian; Peter Boekstegers; Rabea Hinkel; Stefanie Schinkel; Barbara Leuchs; Jochen Ludwig; Gang Qiu; Christophe Weber; Philip Raake; Walter J Koch; Hugo A Katus; Oliver J Müller; Patrick Most
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

6.  Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue.

Authors:  Sven T Pleger; Patrick Most; Matthieu Boucher; Stephen Soltys; J Kurt Chuprun; Wiebke Pleger; Erhe Gao; Abhijit Dasgupta; Giuseppe Rengo; Andrew Remppis; Hugo A Katus; Andrea D Eckhart; Joseph E Rabinowitz; Walter J Koch
Journal:  Circulation       Date:  2007-04-30       Impact factor: 29.690

Review 7.  Endothelial nitric oxide (NO) and its pathophysiologic regulation.

Authors:  Anuran Chatterjee; Stephen M Black; John D Catravas
Journal:  Vascul Pharmacol       Date:  2008-07-20       Impact factor: 5.773

8.  Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice.

Authors:  Costanza Emanueli; Galliam Graiani; Maria B Salis; Sergio Gadau; Elisa Desortes; Paolo Madeddu
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

9.  Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia.

Authors:  C Emanueli; A Minasi; A Zacheo; J Chao; L Chao; M B Salis; S Straino; M G Tozzi; R Smith; L Gaspa; G Bianchini; F Stillo; M C Capogrossi; P Madeddu
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

10.  Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer.

Authors:  Costanza Emanueli; Maria B Salis; Sophie Van Linthout; Marco Meloni; Elisa Desortes; Jean-Sebastien Silvestre; Michel Clergue; Carlos D Figueroa; Sergio Gadau; Gianluigi Condorelli; Paolo Madeddu
Journal:  Circulation       Date:  2004-09-13       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.